The lymph node ratio predicts cancer-specific survival of node-positive non-small cell lung cancer patients: a population-based SEER analysis

Table 2 Competing risks regression analysis with separate inclusion of the lymph node ratio (LNR) and pN stage as a covariate

Characteristics	SHR	P	SHR	P
LNR classification
LNR1	1(Reference)
LNR2	1.56 (1.47–1.67)	< 0.001
LNR3	2.54 (2.30–2.80)	< 0.001
N stage
N1			1 (Reference)
N2			1.54 (1.45–1.63)	< 0.001
N3			2.81 (2.32–3.41)	< 0.001
Sex
Female	1(Reference)		1(Reference)
Male	1.23 (1.16–1.30)	< 0.001	1.21 (1.134–1.29)	< 0.001
Race
White	1(Reference)		1(Reference)
Black	0.94 (0.85–1.05)	0.262	0.97 (0.87–1.07)	0.506
Others	0.90 (0.81–1.00)	0.040	0.88 (0.79–0.98)	0.020
Primary site
Upper lobe	1(Reference)		1(Reference)
Lowerlobe	1.08 (1.01–1.15)	0.018	1.11 (1.04–1.18)	0.001
Mainbronchus	1.20 (0.96–1.49)	0.103	1.21 (0.98–1.51)	0.083
Middlelobe	0.93 (0.81–1.06)	0.290	1.03 (0.91–1.18)	0.625
Overlapping/NOS	1.28 (1.10–1.49)	0.001	1.30 (1.12–1.52)	< 0.001
Grade
I/II	1(Reference)		1(Reference)
III/IV	1.23 (1.16–1.31)	< 0.001	1.25 (1.18–1.33)	< 0.001
Histology
Adenocarcinoma	1(Reference)		1(Reference)
Squamous	0.92 (0.86–0.99)		0.91 (0.84–0.97)	0.008
Others	1.15 (1.05–1.25)	0.002	1.14 (1.04–1.24)	0.003
T stage		0.030
T1	1(Reference)
T2	1.32 (1.23–1.412)	< 0.001	1.29 (1.199–1.38)	< 0.001
T3	1.85 (1.62–2.12)	< 0.001	1.78 (1.56–2.04)	< 0.001
T4	1.82 (1.64–2.01)	< 0.001	1.82 (1.64–2.01)	< 0.001

ISSN: 1749-8090